<DOC>
	<DOC>NCT01453504</DOC>
	<brief_summary>The purpose of this trial is 1. to determine the recommended dose of everolimus for a subsequent Phase II trial 2. to determine the efficacy of everolimus plus DHAP</brief_summary>
	<brief_title>Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>relapsed or refractory Hodgkin Lymphoma age 1860 histology confirmed relapse previous therapy with mTOR inhibitor current CNS involvement other primary malignant disease within the last 3 years</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>